Abstract
Genital human papillomavirus (HPV) infection is the most common sexually transmitted infection, and virtually all cases of cervical cancer are attributable to infection by a subset of HPVs (reviewed in ref. 1). Despite the high incidence of HPV infection and the recent development of a prophylactic vaccine that confers protection against some HPV types2, many features of HPV infection are poorly understood. It remains worthwhile to consider other interventions against genital HPVs, particularly those that target infections not prevented by the current vaccine. However, productive papillomavirus infection is species- and tissue-restricted, and traditional models use animal papillomaviruses that infect the skin or oral mucosa3. Here we report the development of a mouse model of cervicovaginal infection with HPV16 that recapitulates the establishment phase of papillomavirus infection. Transduction of a reporter gene by an HPV16 pseudovirus was characterized by histology and quantified by whole-organ, multispectral imaging. Disruption of the integrity of the stratified or columnar genital epithelium was required for infection, which occurred after deposition of the virus on the basement membrane underlying basal keratinocytes. A widely used vaginal spermicide, nonoxynol-9 (N-9), greatly increased susceptibility to infection. In contrast, carrageenan, a polysaccharide present in some vaginal lubricants, prevented infection even in the presence of N-9, suggesting that carrageenan might serve as an effective topical HPV microbicide.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma
International Journal of Clinical Oncology Open Access 24 April 2023
-
Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19
Journal of Nanobiotechnology Open Access 25 November 2021
-
Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
BMC Proceedings Open Access 12 August 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Trottier, H. & Franco, E.L. The epidemiology of genital human papillomavirus infection. Vaccine (2005).
Lowy, D.R. & Schiller, J.T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116, 1167–1173 (2006).
Campo, M.S. Animal models of papillomavirus pathogenesis. Virus Res. 89, 249–261 (2002).
Buck, C.B., Pastrana, D.V., Lowy, D.R. & Schiller, J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751–757 (2004).
Buck, C.B., Thompson, C.D., Pang, Y.Y., Lowy, D.R. & Schiller, J.T. Maturation of papillomavirus capsids. J. Virol. 79, 2839–2846 (2005).
Richards, R.M., Lowy, D.R., Schiller, J.T. & Day, P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 103, 1522–1527 (2006).
Pastrana, D.V. et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216 (2004).
Pyeon, D., Lambert, P.F. & Ahlquist, P. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. USA 102, 9311–9316 (2005).
Buck, C.B. et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2, e69 (2006).
Pastrana, D.V. et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337, 365–372 (2005).
Reuter, J.D., Gomez, D., Brandsma, J.L., Rose, J.K. & Roberts, A. Optimization of cottontail rabbit papilloma virus challenge technique. J. Virol. Methods 98, 127–134 (2001).
Shaner, N.C. et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat. Biotechnol. 22, 1567–1572 (2004).
Roberts, J.N. et al. Infection of murine vaginal or endocervical mucosa with human papillomavirus pseudovirions. Nat. Protoc. published online July 2007 (doi:10.1038/nprot.2007.235).
Gimenez-Conti, I.B. et al. Expression of keratins in mouse vaginal epithelium. Differentiation 56, 143–151 (1994).
Roden, R.B. et al. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J. Virol. 75, 10493–10497 (2001).
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D.R. & Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89, 12180–12184 (1992).
Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002).
Harper, D.M. et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757–1765 (2004).
Niruthisard, S., Roddy, R.E. & Chutivongse, S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm. Dis. 18, 176–179 (1991).
Patton, D.L., Kidder, G.G., Sweeney, Y.C., Rabe, L.K. & Hillier, S.L. Effects of multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal epithelium in the pigtailed macaque (Macaca nemestrina). Am. J. Obstet. Gynecol. 180, 1080–1087 (1999).
Culp, T.D., Budgeon, L.R., Marinkovich, M.P., Meneguzzi, G. & Christensen, N.D. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J. Virol. 80, 8940–8950 (2006).
Wilkinson, D., Tholandi, M., Ramjee, G. & Rutherford, G.W. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect. Dis. 2, 613–617 (2002).
Hermonat, P.L., Daniel, R.W. & Shah, K.V. The spermicide nonoxynol-9 does not inactivate papillomavirus. Sex. Transm. Dis. 19, 203–205 (1992).
Coggins, C. et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76, 480–483 (2000).
Spieler, R. Seaweed compound's anti-HIV efficacy will be tested in southern Africa. Lancet 359, 1675 (2002).
Maguire, R.A., Zacharopoulos, V.R. & Phillips, D.M. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex. Transm. Dis. 25, 494–500 (1998).
Acknowledgements
This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. We thank S.H. Yuspa and other members of the In Vitro Pathogenesis section of the Laboratory of Cancer Biology and Genetics at the US National Cancer Institute for technical assistance and guidance with antibody selection and tissue staining.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Systemic hormonal pretreatment before pseudovirus challenge. (PDF 59 kb)
Supplementary Fig. 2
Typical confocal microscopic appearance of the cervicovaginal epithelium after pseudovirus challenge. (PDF 268 kb)
Supplementary Fig. 3
Pseudovirus reporter gene expression over time. (PDF 35 kb)
Supplementary Fig. 4
Target cell identification with anti-keratin6 antibody staining. (PDF 320 kb)
Supplementary Fig. 5
Requirement of L2 for infection of the genital epithelium. (PDF 33 kb)
Supplementary Fig. 6
Virus-like particle (VLP) immunization protects against type-specific pseudovirus challenge. (PDF 41 kb)
Supplementary Fig. 7
Basement membrane staining of laminin-5. (PDF 72 kb)
Supplementary Table 1
Performance of reporter constructs in mouse challenge model. (PDF 26 kb)
Rights and permissions
About this article
Cite this article
Roberts, J., Buck, C., Thompson, C. et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13, 857–861 (2007). https://doi.org/10.1038/nm1598
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1598
This article is cited by
-
Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma
International Journal of Clinical Oncology (2023)
-
Human papillomaviruses: diversity, infection and host interactions
Nature Reviews Microbiology (2022)
-
Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
BMC Proceedings (2021)
-
Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19
Journal of Nanobiotechnology (2021)
-
Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer
Acta Pharmacologica Sinica (2021)